Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer takes on AstraZeneca and Merck & Co in prostate cancer; AstraZeneca’s gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi and Medicines Patent Pool strike deal for oral COVID antiviral; and Intercept sticks with NASH plans despite missed endpoint.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 7 October 2022, including: Pfizer Inc. takes on AstraZeneca PLC and Merck & Co., Inc. in prostate cancer; AstraZeneca’s gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi & Co. Ltd. and Medicines Patent Pool (MPP) strike deal for oral COVID antiviral; and Intercept Pharmaceuticals, Inc. sticks with NASH plans despite missed endpoint.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer’s Talzenna Takes On Top Dog Lynparza In Prostate Cancer" - Scrip, 4 Oct, 2022.)
(Also see "AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope" - Scrip, 4 Oct, 2022.)
(Also see "Ex-Sanofi Partnering Chief Wants AI Start-Up Owkin To Be Industry Leader" - Scrip, 4 Oct, 2022.)
(Also see "Shionogi's Oral COVID Drug Set For Global Access Through MPP" - Scrip, 4 Oct, 2022.)
(Also see "Intercept Not Changing NDA Refiling Plans After OCA Misses NASH Cirrhosis Endpoint" - Scrip, 30 Sep, 2022.)